Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Search articles, authors, keywords, DOl and etc.
To explore the status quo of aromatase inhibitor (AIs)-induced arthralgia (AIA) in elderly patients with breast cancer and to analyze its influencing factors.
A total of 150 elderly breast cancer patients who received AIs in the Tenth Affiliated Hospital of Southern Medical University were selected as the study subjects. According to occurrence of AIA, the patients were divided into an AIA group and a non-AIA group. Based on the numerical rating scale (NRS) scores of AIA patients, they were further divided into a mild pain group (NRS score of 1-3 points) and a moderate pain group (NRS score of 4-6 points). The data on the time of AIA onset, distribution of pain joints, and pain intensity were collected. SPSS 27.0 was used for data processing. According to the data type, t test or Chi-square test was used for comparison between groups. Binary logistic regression was used to analyze the influencing factors for AIA in elderly breast cancer patients treated with AIs.
All the 150 elderly patients with breast cancer took AIs for more than one month, and 72 patients developed AIA with an incidence of 48.00%. Among 72 AIA patients with, the proportions of those developing AIA within the 1st month and 2nd month of medication were 27.78% (20/72) and 43.06% (31/72), and only 6.94% (5/72) of the patients developed AIA after 3 months of medication. The pain were mainly localized in the hand/wrist and knees, and 87.50% (63/72) of patients had NRS score of 1-3 points. Binary logistic regression analysis suggested that BMI ≥ 24.0 kg/m2 (OR=1.514, 95%CI 1.068-2.147) and taxane chemotherapy (OR=2.130, 95%CI 1.111-4.083) were risk factors for AIA occurrence, and calcium carbonate D3 supplementation (OR=0.415, 95%CI 0.244-0.708) was a protective factor. Among AIA patients, 63 (87.50%) experienced mild pain and 9 (12.50%) moderate pain. The proportions of patients with age > 79 years, BMI ≥ 24.0 kg/m2, never exercising, and anxiety were higher in the moderate pain group than those in the mild pain group, while the proportion of patients receiving calcium carbonate D3 supplementation was lower in the moderate pain group than that in mild pain group; all differences were statistically significan (all P< 0.05).
The incidence of AIA is high in elderly breast cancer patients treated with AIs. BMI ≥ 24.0 kg/m2 and taxane chemotherapy are risk factors for AIA, and calcium carbonate D3 supplementation is a protective factor. Additionally, age, BMI, exercise frequency, anxiety, and calcium carbonate D3 supplementation are factors affecting the pain intensity in patients with AIA.
Comments on this article